Olga Koshelskaya

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5592143/publications.pdf

Version: 2024-02-01

54 3,558 8 26 papers citations h-index g-index

55 55 4225 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2017, 377, 1228-1239.	27.0	1,455
2	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet, The, 2018, 392, 1519-1529.	13.7	1,179
3	Effect of Two Intensive Statin Regimens on Progression of Coronary Disease. New England Journal of Medicine, 2011, 365, 2078-2087.	27.0	731
4	Physicians' guideline adherence is associated with longâ€ŧerm heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. European Journal of Heart Failure, 2019, 21, 921-929.	7.1	86
5	Effect of Onceâ€Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial. Journal of the American Heart Association, 2018, 7, e009304.	3.7	19
6	Hypertrophy and Insulin Resistance of Epicardial Adipose Tissue Adipocytes: Association with the Coronary Artery Disease Severity. Biomedicines, 2021, 9, 64.	3.2	19
7	System of Matrix Metalloproteinases and Cytokine Secretion in Type 2 Diabetes Mellitus and Impaired Carbohydrate Tolerance Associated with Arterial Hypertension. Bulletin of Experimental Biology and Medicine, 2014, 156, 635-638.	0.8	15
8	Visceral obesity and cardiometabolic risk: features of hormonal and immune regulation. Obesity and Metabolism, 2017, 14, 3-10.	1.2	15
9	Frequency of monocyte subsets is linked to the severity of atherosclerosis in patients with ischemic		

#	Article	IF	CITATIONS
19	EFFECT OF THE COMBINED ANTIHYPERTENSIVE THERAPY WITH TARGET BLOOD PRESSURE ACHIEVEMENT ON INTRARENAL BLOOD FLOW IN PATIENTS WITH TYPE 2 DIABETES. Rational Pharmacotherapy in Cardiology, 2012, 8, 433-440.	0.8	1
20	Physiological basis of the improvement of movement accuracy on the basis of stabilographic training with biological feedback. Human Physiology, 2015, 41, 404-411.	0.4	1
21	T-helper-1, T-helper-17, T-regulatory lymphocytes in hypertensive patients with diabetes mellitus type 2 or impaired glucose tolerance: association with clinical and metabolic parameters in a case control study. Translational Medicine Communications, 2016, 1, .	1.4	1
22	FOXP3+ T-REGULATORY LYMPHOCYTES IN HYPERTENSIVE PATIENTS. Journal of Hypertension, 2019, 37, e153.	0.5	1
23	Circulating FoxP3+ T-lymphocytes in chronic coronary artery disease: Associations with the severity of atherosclerosis and lipid metabolism. Sibirskij žurnal KliniÄeskoj I Ã⁻ksperimentalʹnoj Mediciny, 2021, 36, 45-51.	0.4	1
24	GLYCEMIA CONTROL, INSULIN RESISTANCE, AND FUNCTIONAL ACTIVITY OF T-HELPER SUBPOPULATIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. Russian Journal of Cardiology, 2014, , 95-101.	1.4	1
25	Prediction of basal glycaemia dynamics during treatment with 6-month lipid-lowering therapy in patients at high risk of cardiovascular disease. Diabetes Mellitus, 2017, 20, 374-383.	1.9	1
26	Macrophages in epicardial adipose tissue and serum NT-proBNP in patients with stable coronary artery disease. Medical Immunology (Russia), 2022, 24, 389-394.	0.4	1
27	Clinical efficacy of cilazapril in patients with essential hypertension and type II diabetes mellitus. Pharmacological Research, 1995, 31, 325.	7.1	0
28	Metabolic effects of Captopril in hypertensive patients with noninsulin-dependent diabetes mellitus and hyperlipidemia. Pharmacological Research, 1995, 31, 325.	7.1	0
29	INTRARENAL BLOOD FLOW DOPPLER SPECTRA IN DIABETIC PATIENTS AND HYPERTENSIVE DIABETIC PATIENTS: PP.17.146. Journal of Hypertension, 2010, 28, e294.	0.5	0
30	DISPROPORTIONAL INCREASE IN SYSTOLIC BLOOD PRESSURE AND TARGET ORGAN DAMAGE SIGNS IN HYPERTENSIVE DIABETIC PATIENTS: PP.17.150. Journal of Hypertension, 2010, 28, e295.	0.5	0
31	MS453 LIPID AND PLEOTROPIC EFFECTS OF LONG-TERM ATORVASTATIN THERAPY IN HYPERTENSIVE DIABETIC AND NON-DIABETIC PATIENTS WITH CORONARY ARTERY DISEASE. Atherosclerosis Supplements, 2010, 11, 201.	1.2	0
32	DIFFERENT EFFECTS OF TARGET BLOOD PRESSURE ACHIEVED DURING COMBINED ANTIHYPERTENSIVE THERAPY WITH AND WITHOUT RAAS INHIBITORS ON INTRARENAL VASCULAR RESISTANCE IN HYPERTENSIVE DIABETIC PATIENTS. Journal of Hypertension, 2011, 29, e398.	0.5	0
33	DYNAMICS OF INTRARENAL VASCULAR RESISTANCE UNDER LONG-TERM ANTIHYPERTENSIVE MONOTHERAPY WITH ACE INHIBITORS AND CALCIUM ANTAGONISTS IN HYPERTENSIVE DIABETIC PATIENTS. Journal of Hypertension, 2011, 29, e235.	0.5	0
34	EFFICACY OF COMBINED ANTIHYPERTENSIVE THERAPY IN ACHIEVEMENT OF TARGET BLOOD PRESSURE IN DIABETIC PATIENTS. Rational Pharmacotherapy in Cardiology, 2012, 8, 667-674.	0.8	0
35	Lipid and pleotropic effects of atorvastatin therapy and its combination with ezetimibe in patients with coronary artery disease and diabetes. Atherosclerosis, 2014, 235, e257.	0.8	0
36	Functional activity of th1-lymphocytes depends on the degree of insulin resistance in patients with diabetes mellitus type 2. Atherosclerosis, 2014, 235, e141.	0.8	0

#	Article	IF	CITATIONS
37	PP.05.29. Journal of Hypertension, 2015, 33, e176.	0.5	0
38	PP.05.30. Journal of Hypertension, 2015, 33, e176.	0.5	0
39	PP.05.31. Journal of Hypertension, 2015, 33, e176-e177.	0.5	O
40	[PP.12.26] METABOLIC EFFECTS OF DIFFERENT LIPID-LOWERING THERAPY REGIMENS IN HYPERTENSIVE PATIENTS WITH HIGH CARDIOVASCULAR RISK. Journal of Hypertension, 2017, 35, e193-e194.	0.5	0
41	[PP.18.24] INTRARENAL VASCULAR RESISTANCE AND CIRCADIAN BLOOD PRESSURE PROFILE IN HYPERTENSIVE DIABETIC PATIENTS. Journal of Hypertension, 2017, 35, e237-e238.	0.5	O
42	THE EFFECT OF STATIN THERAPY ON MONOCYTE SUBPOPULATIONS IN PATIENTS WITH ARTERIAL HYPERTENSION AND OBESITY. Journal of Hypertension, 2018, 36, e97.	0.5	0
43	HEMODYNAMIC FACTORS ASSOCIATED WITH INADEQUATE CONTROL OF NOCTURNAL HYPERTENSION DURING DIFFERENT COMBINED ANTIHYPERTENSIVE THERAPY IN HYPERTENSIVE DIABETIC PATIENTS. Journal of Hypertension, 2018, 36, e191.	0.5	0
44	THE RELATIONSHIP BETWEEN PULSE WAVE VELOCITY, RENAL RESISTIVE INDEX AND MEASURES OF OBESITY IN HYPERTENSIVE PATIENTS WITH CORONARY ARTERY DISEASE. Journal of Hypertension, 2019, 37, e149.	0.5	0
45	MARKERS OF CHRONIC KIDNEY DISEASE AND RENAL HEMODYNAMICS DISTURBANCES IN PATIENTS WITH WELL-MEDICALLY CONTROLLED HYPERTENSION. Journal of Hypertension, 2019, 37, e261.	0.5	0
46	SUBCELLULAR LOCALIZATION OF FoxP3 TRANSCRIPTION FACTOR IN PATIENTS WITH ACUTE CORONARY SYNDROME: COMPARATIVE ANALYSIS AND PROSPECTIVE OBSERVATION. Medical Immunology (Russia), 2021, 23, 731-736.	0.4	0
47	MRI assessment of the abdominal adipose tissue and the state of the abdominal aorta in patients with coronary artery disease: association with metabolic disorders. Bulletin of Siberian Medicine, 2021, 20, 95-104.	0.3	O
48	EFFECT OF LONG-TERM ACE INHIBITION ON BLOOD PRESSURE PROFILE AND INTRARENAL BLOOD FLOW VELOCITY DOPPLER SPECTRA IN HYPERTENSIVE DIABETIC PATIENTS. Journal of Hypertension, 2000, 18, S106.	0.5	0
49	ABNORMAL CIRCADIAN RHYTHM AND VARIABILITY OF BLOOD PRESSURE IN HYPERTENSIVE PATIENTS WITH DIABETES MELLITUS. Journal of Hypertension, 2000, 18, S45-S46.	0.5	O
50	HYPOGLYCEMIC THERAPY, VASCULAR FUNCTION AND CYTOCINES. Journal of Hypertension, 2004, 22, S49.	0.5	0
51	TRIMETAZIDINE AND ACE INHIBITORS THERAPY IN HYPERTENSIVE DIABETIC PATIENTS. Journal of Hypertension, 2004, 22, S364.	0.5	O
52	Algorithm for differential administration of combination antihypertensive therapy in patients with Type 2 diabetes mellitus. Russian Journal of Cardiology, 2013, , 74-82.	1.4	0
53	FOXP3+T-REGULATORY LYMPHOCYTES AND AUTOANTIBODIES IN PATIENTS WITH ARTERIAL HYPERTENSION, ASSOCIATED WITH DIABETES MELLITUS TYPE 2 AND IMPAIRED GLUCOSE TOLERANCE. Medical Immunology (Russia), 2014, 15, 155.	0.4	0
54	Morphological and functional characteristics of retrosternal adipose tissue and their relation to arterial stiffness parameters in patients after coronary artery bypass grafting. Bulletin of Siberian Medicine, 2020, 19, 63-71.	0.3	0